Immune checkpoint inhibitors in the peri-operative setting in renal cell carcinoma: A meta-analysis of the randomized clinical trials. Cabozantinib in combination with atezolizumab in non-clear cell ...
Efficacy and tolerability of high dose interleukin-2 (HD IL-2) after disease progression on targeted therapy (TT) for metastatic renal cell carcinoma (mRCC). Linear regression analysis of factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback